Emerging data also highlight potential crosstalk between NRF2 and NOTCH signaling axes, which may synergistically drive tumor aggressiveness and resistance phenotypes, resulting in significant clinical implications as detailed in this section [223]. This evidence concerns the gene NFE2L2 and neoplasm.